Edition:
United States

NewLink Genetics Corp (NLNK.OQ)

NLNK.OQ on NASDAQ Stock Exchange Global Market

8.15USD
15 Dec 2017
Change (% chg)

$-0.10 (-1.21%)
Prev Close
$8.25
Open
$8.24
Day's High
$8.39
Day's Low
$7.99
Volume
776,140
Avg. Vol
521,528
52-wk High
$25.11
52-wk Low
$5.91

Chart for

About

NewLink Genetics Corporation is a clinical-stage immuno-oncology company focused on discovering, developing and commercializing immunotherapeutic products for the treatment of cancer. The Company's portfolio includes biologic and small-molecule immunotherapy product candidates for a range of oncology indications. Its biologic... (more)

Overall

Beta: 1.10
Market Cap(Mil.): $295.21
Shares Outstanding(Mil.): 36.22
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 198.20 16.04
EPS (TTM): -- -- --
ROI: -- -11.76 34.69
ROE: -- -36.72 15.46

BRIEF-Newlink Genetics, Bps And Merck Sharp & Dohme Amended License & Collaboration Agreement

* NEWLINK GENETICS - ON DEC 5, BPS AND MERCK SHARP & DOHME CORP AMENDED LICENSE & COLLABORATION AGREEMENT DATED NOV 21, 2014

Dec 11 2017

BRIEF-NewLink Genetics reports Q3 loss per share $0.69

* NewLink Genetics Corp - ‍Expect to end 2017 with approximately $150 million in cash and equivalents​

Nov 02 2017

BRIEF-Newlink genetics announces FDA orphan-drug designation for Indoximod

* Newlink Genetics announces FDA orphan-drug designation for Indoximod

Oct 30 2017

BRIEF-NewLink Genetics announces proposed public offering of common stock

* NewLink Genetics announces proposed public offering of common stock

Oct 03 2017

BRIEF-NewLink Genetics forecasts co will have about $100 million in cash and cash equivalents on balance sheet

* NewLink Genetics - forecasts that co will have about $100 million in cash and cash equivalents on its balance sheet as of December 31, 2017 - SEC filing Source text for Eikon: Further company coverage:

Sep 25 2017

BRIEF-NewLink Genetics announces clinical collaboration to evaluate IO-based combination therapies in pancreatic cancer

* NewLink Genetics announces clinical collaboration to evaluate IO-based combination therapies in pancreatic cancer

Sep 25 2017

BRIEF-NewLink Genetics announces clinical collaboration with AstraZeneca​

* Newlink Genetics announces clinical collaboration to evaluate IO-based combination therapies in pancreatic cancer

Sep 25 2017

BRIEF-NewLink Genetics Q2 loss per share $0.57

* NewLink Genetics - ‍expect to end 2017 with approximately $75 million in cash and equivalents, which excludes any cash that may be received from financing​

Jul 28 2017

BRIEF-Newlink Genetics ‍receives notice of allowance from USPTO covering indoximod salts and prodrugs​

* Newlink Genetics says ‍receives notice of allowance from USPTO covering indoximod salts and prodrugs​ Source text for Eikon: Further company coverage:

Jul 10 2017

Competitors

  Price Chg
Astellas Pharma Inc (4503.T) ¥1,448 +16.50
Pfizer Inc. (PFE.N) $37.20 +0.74
Novartis AG (NOVN.S) CHF84.35 +0.55
Merck & Co., Inc. (MRK.N) $56.24 +0.23
Roche Holding Ltd. (ROG.S) CHF245.10 +1.00
Roche Holding Ltd. (RO.S) CHF245.90 +2.50
Abbott Laboratories (ABT.N) $55.50 +0.77
Sanofi SA (SASY.PA) €74.49 +0.94
AstraZeneca plc (AZN.L) 4,911.50 +30.50
GlaxoSmithKline plc (GSK.L) 1,306.00 +11.00

Earnings vs. Estimates